Addressing the Cold Reality of mRNA Vaccine Stability

Abstract

As mRNA vaccines became the frontrunners in late-stage clinical trials to fight the COVID-19 pandemic, challenges surrounding their formulation and stability became readily apparent. In this commentary, we first describe company proposals, based on available public information, for the (frozen) storage of mRNA vaccine drug products across the vaccine supply chain. We then review the literature on the pharmaceutical stability of mRNA vaccine candidates, including attempts to improve their stability, analytical techniques to monitor their stability, and regulatory guidelines covering product characterization and storage stability. We conclude that systematic approaches to identify the key physicochemical degradation mechanism(s) of formulated mRNA vaccine candidates are currently lacking. Rational design of optimally stabilized mRNA vaccine formulations during storage, transport, and administration at refrigerated or ambient temperatures should thus have top priority in the pharmaceutical development community. In addition to evidence of human immunogenicity against multiple viral pathogens, including compelling efficacy results against COVID-19, another key strength of the mRNA vaccine approach is that it is readily adaptable to rapidly address future outbreaks of new emerging infectious diseases. Consequently, we should not wait for the next pandemic to address and solve the challenges associated with the stability and storage of formulated mRNA vaccines.

Cited by papers we hold 9

• Algorithm for optimized mRNA design improves stability and immunogenicity · 2023
  No notice
• Therapeutic cancer vaccines: advancements, challenges and prospects · 2023
  No notice
• Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2 · 2023
  No notice
• mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability · 2021
  No notice
• A novel mechanism for the loss of mRNA activity in lipid nanoparticle delivery systems · 2021
  No notice
• Temperature‐Controlled Conversion of Boc‐Protected Methylene Blue: Advancing Solid‐State Time‐Temperature Indicators · 2021
  Not checked
• Perspectives on RNA Vaccine Candidates for COVID-19 · 2021
  Not checked
• mRNA vaccines for COVID-19: what, why and how · 2021
  No notice
• Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.